MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597859 | Name: Ceronapril

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ceronapril is an angiotensin-Converting Enzyme Inhibitor.

Chemical Structure

Ceronapril
CAS#111223-26-8

Theoretical Analysis

MedKoo Cat#: 597859

Name: Ceronapril

CAS#: 111223-26-8

Chemical Formula: C21H33N2O6P

Exact Mass: 440.2076

Molecular Weight: 440.47

Elemental Analysis: C, 57.26; H, 7.55; N, 6.36; O, 21.79; P, 7.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
120122-26-1;
Synonym
Ceronapril; Ceronaprilum; SQ 29,852; SQ-29,852; SQ29,852; SQ 29852; SQ-29852; SQ29852; 120122-26-1;
IUPAC/Chemical Name
((2S)-6-amino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)-L-proline
InChi Key
IFYLTXNCFVRALQ-OALUTQOASA-N
InChi Code
InChI=1S/C21H33N2O6P/c22-14-6-4-13-19(20(24)23-15-8-12-18(23)21(25)26)29-30(27,28)16-7-5-11-17-9-2-1-3-10-17/h1-3,9-10,18-19H,4-8,11-16,22H2,(H,25,26)(H,27,28)/t18-,19-/m0/s1
SMILES Code
O=C(O)[C@H]1N(C([C@@H](OP(CCCCC2=CC=CC=C2)(O)=O)CCCCN)=O)CCC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 440.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Weiner I, Smith AD, Rawlins JN, Feldon J. A neuroleptic-like effect of ceronapril on latent inhibition. Neuroscience. 1992 Jul;49(2):307-15. PubMed PMID: 1359453. 2: Chen BZ, Mendelsohn FA. Effect of acute and chronic administration of ceronapril on angiotensin converting enzyme in plasma, kidney, lung, brain regions and cerebrospinal fluid of rats. Neuropharmacology. 1992 Sep;31(9):929-35. PubMed PMID: 1331844. 3: Cutler NR, Sramek JJ, Luna A, Mena I, Brass EP, Kurtz NM, Brennan JJ. Effect of the ACE inhibitor ceronapril on cerebral blood flow in hypertensive patients. Ann Pharmacother. 1996 Jun;30(6):578-82. PubMed PMID: 8792940. 4: Tu JI, Brennan J, Stouffer B, Mantha S, Turabi N, Tsay HM. Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers. Ther Drug Monit. 1992 Jun;14(3):209-19. PubMed PMID: 1412607. 5: Weiner I, Tarrasch R, Hasson O, Forian R, Smith AD, Rawlins JN, Feldon J. The effects of chronic administration of ceronapril on the partial reinforcement extinction effect and latent inhibition in rats. Behav Pharmacol. 1994 Jun;5(3):306-314. PubMed PMID: 11224280. 6: Morishita R, Rakugi H, Higaki J, Tomita N, Nakamura F, Yu H, Katsuya T, Mikami H, Ogihara T. Differential regulation of brain angiotensin II in genetically hypertensive and normotensive rats after nephrectomy. Blood Press. 1994 Jul;3(4):265-9. PubMed PMID: 7994453. 7: Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res. 1992 Nov;9(11):1480-6. PubMed PMID: 1475237. 8: Katahira K, Mikami H, Otsuka A, Moriguchi A, Kohara K, Higashimori K, Okuda N, Nagano M, Morishita R, Ogihara T. Differential control of vascular tone and heart rate by different amino acid neurotransmitters in the rostral ventrolateral medulla of the rat. Clin Exp Pharmacol Physiol. 1994 Jul;21(7):545-56. PubMed PMID: 7982287. 9: Sudilovsky A, Cutler NR, Sramek JJ, Wardle T, Veroff AE, Mickelson W, Markowitz J, Repetti S. A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease. Alzheimer Dis Assoc Disord. 1993 Summer;7(2):105-11. PubMed PMID: 8347328. 10: Barnes JM, Barnes NM, Costall B, Coughlan J, Kelly ME, Naylor RJ, Tomkins DM, Williams TJ. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S63-71. PubMed PMID: 1382167. 11: Costall B, Domeney AM, Gerrard PA, Horovitz ZP, Kelly ME, Naylor RJ, Tomkins DM. Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset. Pharmacol Biochem Behav. 1990 May;36(1):13-20. PubMed PMID: 2112256. 12: Kohara K, Brosnihan KB, Ferrario CM. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides. 1993 Sep-Oct;14(5):883-91. PubMed PMID: 8284265. 13: Robertson JM, Harding S, Grupp LA. The reduction in alcohol intake produced by enalapril is not attenuated by centrally administered angiotensin inhibitors. Alcohol. 1994 Jul-Aug;11(4):295-9. PubMed PMID: 7945983. 14: Sasaki J, Koga S, Kato K, Takii M, Sakai K, Kawasaki K, Kagimoto M, Doi Y, Takada K, Sakaue A, et al. Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. Int J Clin Pharmacol Ther Toxicol. 1993 Feb;31(2):83-8. PubMed PMID: 8458681. 15: Ohta Y, Chikugo T, Suzuki T, Chichibu S. Electroencephalographic evaluation of the therapeutic efficiency of antihypertensive agents on M-SHRSP. Clin Exp Pharmacol Physiol Suppl. 1995 Dec;22(1):S377-9. PubMed PMID: 9072435. 16: Matsuzaki K, Mukai M, Sumimoto T, Murakami E. Effects of ACE inhibitors versus calcium antagonists on left ventricular morphology and function in patients with essential hypertension. Hypertens Res. 1997 Mar;20(1):7-10. PubMed PMID: 9101306. 17: Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol. 1991 Aug 6;200(2-3):289-92. PubMed PMID: 1664329. 18: Barnes NM, Costall B, Egli P, Horovitz ZP, Ironside JW, Naylor RJ, Williams TJ. The ACE inhibitor [3H]SQ29,852 identifies a high affinity recognition site located in the human temporal cortex. Brain Res Bull. 1990 Jul;25(1):183-5. PubMed PMID: 2207707. 19: Hamada Y, Niisato E, Otori T, Chikugo TA, Ohta Y, Suzuki T, Okamoto K. Ocular fundus changes in malignant or precocious stroke-prone spontaneously hypertensive rats after administration of antihypertensive drugs. Clin Exp Pharmacol Physiol Suppl. 1995 Dec;22(1):S132-3. PubMed PMID: 9072325. 20: Sadoshima S, Nagao T, Ibayashi S, Fujishima M. Inhibition of angiotensin-converting enzyme modulates the autoregulation of regional cerebral blood flow in hypertensive rats. Hypertension. 1994 Jun;23(6 Pt 1):781-5. PubMed PMID: 8206577.